Department of Hematology Sheng Jing Hospital of China Medical University

Wang Hong-tao MD ＆ PhD

1

2Brchireddy P, et al. Nat Rev Cancer. 2015;15(4):201-15.

3James N, et al. Nat Rev Clin Oncol. 2013;10:267-76.

4James N, et al. Nat Rev Clin Oncol. 2013;10:267-76.

A Rambaldi, et al. Leukemial. 2015;29:1-10.5

6

7

CAR-T therapy in our centerDisease

LymphomaTarget antigen

CD19Vector

RetrovirusChemotherapy administered before cell

infusionFludarabine and cyclophosphamide

8

CAR-T therapy in our centerPatie

ntGende

r Age (year

s)Diagnosis

Number of prior

therapies

Number of CAR-T

cells infused

Response (duration in months after CAR-T cell infusion)

1 Female 55 DLBCL 10 25×107 PR (1)

2a* Female 30 DLBCL 11 6.6×107 PR (3)

2b* Female 30 DLBCL 11 5×107 SD (9)

3a* Male 41 DLBCL 11 18×107 PR (1)

3b* Male 41 DLBCL 11 19.6×107 CR (5)

4 Male 10 Burkitt’s Lymphoma 8 7×107 NE

5 Female 62 DLBCL 10 7.6×107 PR (2)

* Patient 2 and 3 were treated twice.Abbreviations: CAR, chimeric antigen receptor; DLBCL, diffuse large B cell lymphoma; PR, partial remission; CR, complete remission; NE, not evaluable for malignancy response because the patient died with sepsis.

Clinical index

9

10

Images

Cytokine Release Syndrome

11

57.15% (4/7)Fever Neurologic toxicity (Patient 1)

PreventionTNF α antagonistCRRT?

Cytokines

12

Cytokines

13

NK cells and B cells

14

T cells

15

Thanks ！

16

2015.8.28